FDA asks Pfizer to pull Viagra TV ads

Share this article:
Pfizer was asked to pull two television ads for Viagra by the FDA, who say the "wild thing" ads make unsubstantiated claims about a return of sexual desire.
The FDA said in a letter that the 30- and 15-second ads also failed to mention major side effects and why some patients should not take Viagra.
The ads, with a voice-over that includes "Remember that guy who used to be called 'wild thing'?" and later says, "He's back," additionally failed to mention the specific condition Viagra is intended for -- erectile dysfunction.
"FDA is not aware of substantial evidence or substantial clinical experience demonstrating this benefit for patients who take Viagra," said the letter from the FDA's DDMAC unit.
The FDA asked the company to respond by Nov. 24 on its intent and plan to comply.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...